An eight-week, multicenter, double-blind, placebo- and paroxetine-controlled study evaluating the efficacy, and tolerability of two fixed doses of SSR149415 (250 mg bid and 100 mg bid) in patients with major depressive disorder
Phase of Trial: Phase II
Latest Information Update: 07 Jul 2009
At a glance
- Drugs SSR 149415 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms LENA
- 07 Jul 2009 Actual end date (1 Sep 2007) and actual patient number (324) added as reported by ClinicalTrials.gov.
- 26 Dec 2007 Status changed from in progress to completed.
- 12 Jul 2007 Status changed from recruiting to in progress.